ReviewAdvances in therapy2020
The Most Severe Stage of Chronic Venous Disease: An Update on the Management of Patients with Venous Leg Ulcers.
Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05319106 (Transplantation of Human Umbilical Cord Derived Mesenchymal Stem Cell for Refractory Skin Ulcer Therapy), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transplantation of Human Umbilical Cord Derived Mesenchymal Stem Cell for Refractory Skin Ulcer Therapy
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Pentoxifylline for Venous Leg Ulcers: An Updated Meta-Analysis.The international journal of lower extremity wounds · 2024Pooled it
- Cost Effectiveness of Venous Leg Ulcer Healing Using Muscle Pump Activation.International wound journal · 2026Trial
- Monitoring and modifying recruitment and retention strategies for an ongoing randomised clinical trial with venous leg ulcer patients: Overcoming barriers to participation.International wound journal · 2023Trial
- Article
- Antimicrobial Strategies for Chronic Cutaneous Ulcers: From Preclinical Nanotechnology to Clinical Practice.International journal of nanomedicine · 2026Review
- Therapeutic applications of natural products in the management of venous diseases: a comprehensive review.Inflammopharmacology · 2025Review
- Unfolded protein responses: Dynamic machinery in wound healing.Pharmacology & therapeutics · 2025Review
- Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.Journal of xenobiotics · 2024Article
- Methods for sampling wound fluid from venous leg ulcers for molecular analyses: A scoping review.International wound journal · 2023Article
- Article
- Gene expression changes in therapeutic ultrasound-treated venous leg ulcers.Frontiers in medicine · 2023Article
- Use of Intralesional and Perilesional Human Recombinant Epidermal Growth Factor (hrEGF) in the Local Treatment of Venous Ulcer - Review Article - Expert Recommendation.Vascular health and risk management · 2023Review
- Antioxidant Potential of Diosmin and Diosmetin against Oxidative Stress in Endothelial Cells.Molecules (Basel, Switzerland) · 2022Article
- Modulatory Effect of Diosmin and Diosmetin on Metalloproteinase Activity and Inflammatory Mediators in Human Skin Fibroblasts Treated with Lipopolysaccharide.Molecules (Basel, Switzerland) · 2022Article
- Understanding Chronic Venous Disease: A Critical Overview of Its Pathophysiology and Medical Management.Journal of clinical medicine · 2021Review
- Leg ulcers in sickle cell disease patients.Jornal vascular brasileiro · 2020Review
- Strategies and challenges in the treatment of chronic venous leg ulcers.World journal of clinical cases · 2020Review
- Measurement of wound area for early analysis of the scar predictive factor.Revista latino-americana de enfermagem · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous leg ulcers (VLUs) are the most severe manifestation of chronic venous disease (CVD). Due to their chronic nature, high recurrence rate and slow healing time, VLUs account for 80% of all leg ulcers seen in patients with CVD. VLUs impose a heavy burden on patients that reduces their quality of life; VLUs also represent a major socioeconomic impact due to the cost and duration of care. The primary medical approach to treating VLUs is local compression therapy in combination with venoactive drug (VAD) pharmacotherapy to promote the reduction of the inflammatory reaction initiated by venous hypertension. Micronized purified flavonoid fraction (MPFF; Daflon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.